We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

SEBIA

Sebia provides clinical protein electrophoresis equipment and reagents for in-vitro diagnostic testing, including sys... read more Featured Products: More products

Download Mobile App





Sebia Presents Innovative Solutions for Screening and Diagnostics

By LabMedica International staff writers
Posted on 22 May 2023
Print article
Image: The new fully automated Alegria 2 instrument (Photo courtesy of Sebia)
Image: The new fully automated Alegria 2 instrument (Photo courtesy of Sebia)

Sebia (Lisses, France) is showcasing its innovative solutions for screening and diagnostics in oncology, metabolic diseases, genetic disorders and autoimmune diseases at WorldLab–EuroMedLab Roma 2023.

At EuroMedLab Rome 2023, Sebia is highlighting the new Alegria 2 instrument, a fully automated, sample-to-result solution. The instrument utilizes ORGENTEC’s unique and comprehensive Alegria Monotest portfolio, boasting over 100 parameters. A key distinguishing feature of the Alegria system is its flexibility to run any test from the wide ORGENTEC portfolio at any given time. Physicians can request tailor-made biomarker profiles to be analyzed for individual patients, ensuring the best possible patient care.

Sebia is presenting its CAPILLARYS 3 range of capillary electrophoresis (CE) instruments, designed for complete automation, rapid protein separation, and high resolution. The Sebia CE instruments are equipped with several parallel capillaries, enabling multiple analyses to be carried out simultaneously, offering scalable throughput. The Sebia CAPILLARYS instruments are currently the most widely used CE systems in clinical labs globally. Alongside its CE capabilities, Sebia is highlighting its gel technique-based solutions. These are implemented on the HYDRASYS instruments to separate hemoglobins and detect major hemoglobin variants via electrophoresis on alkaline agarose gels.

Leveraging its extensive experience in CE technology, Sebia has also adapted it for HbA1c testing, which is being showcased at WorldLab–EuroMedLab Roma 2023. This cutting-edge technology offers labs and clinicians accurate and significant results, enhancing patient management. The clear and precise separation of different hemoglobin fractions enables accurate HbA1c measurement due to the high-resolution separation capabilities of the capillary instruments. Given Sebia’s wide offering of capillary instruments, laboratories have the freedom to choose the platform that best suits their needs, ranging from a benchtop standalone instrument to the TLA configuration.

Related Links:
Sebia

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Clinical Chemistry

view channel
Image: The study demonstrated that electric-field molecular fingerprinting can probe cancer (Photo courtesy of ACS Central Science, 2025, 10.1021/acscentsci.4c02164)

New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma

Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more

Molecular Diagnostics

view channel
Image: The test can find tRNA fragments unique to Parkinson’s disease before patients even have symptoms (Photo courtesy of Shutterstock)

Rapid Blood Test Identifies Pre-Symptomatic Patients with Parkinson’s Disease

Currently, no reliable blood test exists for diagnosing Parkinson’s disease. Instead, physicians rely on observing a patient's movements, but this qualitative method has an error rate of 20%-25% and can... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.